ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "BILAG"

  • Abstract Number: 1765 • ACR Convergence 2021

    Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG A and/or Two BILAG B Domain Scores?

    Ewa Olech1, Faizi Hussain2 and Joan Merrill3, 1IQVIA, Las Vegas, NV, 2IQVIA, Redding, United Kingdom, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…
  • Abstract Number: 1664 • 2017 ACR/ARHP Annual Meeting

    Serum FAS, Ferritin, Igfbp2, sTNFR2 As Markers for Tracking Mucocutaneous and Musculoskeletal Flares in SLE Patients

    Kamala Vanarsa1, Samar Soliman2, Aubrey Swilling3, Joan T. Merrill4 and Chandra Mohan2, 1Biomedical Engineering, University of Houston, houston, TX, 2Biomedical Engineering, University of Houston, Houston, TX, 3University of Houston, houston, TX, 4Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-systemic autoimmune disease, with a broad spectrum of clinical manifestations and unpredictable disease course with periods of…
  • Abstract Number: 1986 • 2017 ACR/ARHP Annual Meeting

    Using the BILAG to Assess the Activity of Lupus in Patients with Fibromyalgia

    Robert S. Katz1, Jessica L. Polyak2 and Frank Leavitt1, 1Rush University Medical Center, Chicago, IL, 2Rheumatology Associates S.C., Chicago, IL

    Background/Purpose:  The BILAG is often used to assess the efficacy of lupus treatments, and is a commonly used tool in lupus drug trials. But the…
  • Abstract Number: 2602 • 2017 ACR/ARHP Annual Meeting

    Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients

    Hiurma Sanchez-Perez1 and David A. Isenberg2, 1Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 2Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Response to Rituximab (RTX) varies significantly between Systemic Lupus Erythematosus (SLE) patients. Ethnicity may play a role in these differences, and a possible relationship…
  • Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials

    Megan E. B. Clowse1, Daniel J Wallace2, Richard Furie3, Michelle Petri4, Marilyn Pike5, Piotr Leszczynski6, C Michael Neuwelt7, Kathryn Hobbs8, Mauro Keiserman9, Liliana Duca10, Kenneth Kalunian11, Sabine Bongardt12, Christian Stach12, Carolyn Beaudot13, Brian Kilgallen13, Catrinel Galateanu14 and Caroline Gordon15,16, 1Rheumatology, Duke University, Durham, NC, 2Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 3North Shore LIJ Health System, Manhasset, NY, 4Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 5Med Pharm Consulting Inc, Cambridge, MA, 6Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, 7Division of Rheumatology, Alameda County Medical Center, Oakland, CA, 8Denver Arthritis Clinic, Denver, CO, 9School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, 10Clinica Neomed, Brasov, Romania, 11UCSD School of Medicine, La Jolla, CA, 12UCB Pharma, Monheim, Germany, 13UCB Pharma, Raleigh, NC, 14UCB Pharma, Brussels, Belgium, 15Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 16NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom

    Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…
  • Abstract Number: 1837 • 2015 ACR/ARHP Annual Meeting

    Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up Study

    Matteo Piga1, Alessandra Gabba1, Mattia Congia1, Fabiana Figus1, Alberto Floris1,2, Alberto Cauli1 and Alessandro Mathieu1, 1University of Cagliari, Cagliari, Italy, 2University of Oxford, Oxford, United Kingdom

    Background/Purpose: SLE patients develop non-deforming non-erosive (NDNE) arthritis in 70-80%, but 5-15% of cases progresses into Jaccoud's arthropathy (JA) a non-erosive deforming arthritis. This study…
  • Abstract Number: 2834 • 2014 ACR/ARHP Annual Meeting

    Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus

    Richard A. Furie1, Michelle Petri2, Caroline Gordon3, Vibeke Strand4, Catrinel Galateanu5, Sabine Bongardt6, Willem Koetse7 and Daniel J. Wallace8, 1Division of Rheumatology and Allergy-Clinical Immunology, North Shore - Long Island Jewish Health System, Great Neck, NY, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 4Biopharmaceutical Consultant, Portola Valley, CA, 5UCB Pharma, Brussels, Belgium, 6UCB Pharma, Monheim, Germany, 7UCB Pharma, Raleigh, NC, 8Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose Epratuzumab is a monoclonal antibody in development for the treatment of systemic lupus erythematosus (SLE) that binds CD22, promoting the natural inhibitory function of…
  • Abstract Number: 676 • 2014 ACR/ARHP Annual Meeting

    Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register

    Emily Sutton1, Kath D. Watson2, David A. Isenberg3, Anisur Rahman4, David Jayne5, Caroline Gordon6, Ben Parker7, David P. D'Cruz8, Munther A. Khamashta9, Pamela Lutalo10, Peter Lanyon11, Benjamin Rhodes12, Bridget Griffiths13, Edward M. Vital14, Chee-Seng Yee15, Christopher Edwards16, Mohammed Akil17, Nicola Erb18, Athiveer Prabu19, Asad A. Zoma20, Neil McHugh21, Hazem Youssef22, Lee-Suan Teh23, Michael W. Beresford24 and Ian N. Bruce25, 1University of Manchester, Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, 2Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 3Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 4Centre for Rheumatology Research, University College London, London, United Kingdom, 5Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 6Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 7Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 8Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, 9Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, 10Peter Gorer Department of Immunobiology, King's College London School of Medicine, London, United Kingdom, 11Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, 12Rheumatology, Queen Elizabeth Hospital, Birmingham, United Kingdom, 13Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 14NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, 15Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, 16Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 17Rheumatology Department, Sheffield South Yorkshire, United Kingdom, 18Rheumatology, Russells Hall Hospital, Dudley, United Kingdom, 19Department of Rheumatology, Worcester Acute Hospitals NHS Trust, Worcester, United Kingdom, 20Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, 21Rheumatology, Royal National Hospital, Bath, United Kingdom, 22Department of Rheumatology, NHS Grampian, Aberdeen, United Kingdom, 23Department of Rhuematology, Royal Blackburn Hospital, Blackburn, United Kingdom, 24Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, 25Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Published efficacy data for rituximab in SLE are complex with positive single-centre case series and negative randomised controlled trials.  This may be due to…
  • Abstract Number: 2542 • 2013 ACR/ARHP Annual Meeting

    Validation Of The Revised Selena Flare Index In Systemic Lupus Erythematosus

    Michelle Petri1, Joan T. Merrill2, R. Maciuca3, John C. Davis Jr.3 and William P. Kennedy3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Genentech, Inc, South San Francisco, CA

    Background/Purpose: The SELENA flare index (SFI) has been used in clinical and clinical trial settings since 2005 (1), but has the limitation that it classifies…
  • Abstract Number: 2548 • 2013 ACR/ARHP Annual Meeting

    Assessment Of Worsening In Lupus Clinical Trials: Do The Endpoints Reflect Medical Judgement?

    Aikaterini Thanou1, Eliza Chakravarty2, Stan Kamp3, Fredonna C. Carthen3 and Joan T. Merrill4, 1Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Discrimination between treatment and placebo is problematic in lupus trials. Recently, composite endpoints have evolved which define response by both improvement in baseline findings…
  • Abstract Number: 2531 • 2013 ACR/ARHP Annual Meeting

    Elevated Combined Serum Free Light Chains Are Associated With Active Disease In Systemic Lupus Erythematosus

    Lakhvir Kaur Assi1, Larissa Lisnevskaia2, Emma Ross3, Richard G Hughes1, Anisur Rahman4 and David A. Isenberg5, 1Clinical R+D, The Binding Site Group Ltd, Birmingham, United Kingdom, 2Oshawa Clinic, Oshawa, ON, Canada, 3Centre for Rheumatology, University College London, London, United Kingdom, 4Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, 5Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom

    Background/Purpose: Chronic and hyper-stimulated B cells are characteristics commonly found in patients with systemic lupus erythematosus (SLE). Due to the complexity and variability observed during…
  • Abstract Number: 1738 • 2013 ACR/ARHP Annual Meeting

    Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study

    Megan E. B. Clowse1, Frederic Houssiau2, Michelle A. Petri3, Brian Kilgallen4, Kenneth Kalunian5, Vibeke Strand6, Sabine Bongardt7, Caroline Gordon8 and Daniel J. Wallace9, 1Rheumatology, Duke University Medical Center, Durham, NC, 2Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4UCB Pharma, Smyrna, GA, 5UCSD School of Medicine, La Jolla, CA, 6Stanford University, Palo Alto, CA, 7UCB Pharma, Brussels, Belgium, 8Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, 9Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA

      Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. In EMBLEMTM (dose-ranging phase IIb study), epratuzumab produced clinically relevant improvements in disease activity in patients…
  • Abstract Number: 1739 • 2013 ACR/ARHP Annual Meeting

    Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study

    Kenneth Kalunian1, Megan E. B. Clowse2, Frederic Houssiau3, Michelle A. Petri4, Brian Kilgallen5, Caroline Gordon6, Vibeke Strand7, Sabine Bongardt8 and Daniel J. Wallace9, 1UCSD School of Medicine, La Jolla, CA, 2Rheumatology, Duke University Medical Center, Durham, NC, 3Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, 4Johns Hopkins University School of Medicine, Baltimore, MD, 5UCB Pharma, Raleigh, NC, 6Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, 7Stanford University, Palo Alto, CA, 8UCB Pharma, Brussels, Belgium, 9Cedars-Sinai Medical Center, Los Angeles, CA

      Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. In EMBLEMTM (a dose-ranging phase IIb study), epratuzumab produced clinically relevant improvements in disease activity in patients…
  • Abstract Number: 1573 • 2013 ACR/ARHP Annual Meeting

    Longer Duration Of B Cell Depletion In Patients With Systemic Lupus Erythematosus Is Associated With a Better Outcome

    Sofia Dias1, Veronica Rodriguez2, Hanh Nguyen3, Charis Pericleous4 and David A. Isenberg5, 1Internal Medicine Department 1, Hospital de Santa Maria, Lisbon, Portugal, 2Hospital Regional Universitario Carlos Haya, Malaga, Spain, 3Centre of Rheumatology. Medicine., University College of London Hospital, london, United Kingdom, 4Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 5Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom

    Background/Purpose: We were alerted to the possibility of very long term B cell depletion (BCD) in Systemic Lupus Erythematosus (SLE) by a patient treated with…
  • Abstract Number: 2621 • 2012 ACR/ARHP Annual Meeting

    Sustained Disease Improvement and Safety Profile Over 1745 Patient-Year Experience (7 years) with Belimumab in Systemic Lupus Erythematosus Patients

    Joan T. Merrill1, Richard A. Furie2, Daniel J. Wallace3, William Stohl4, W. Winn Chatham5, Arthur Weinstein6, James D. McKay, Ellen M. Ginzler8, Z. John Zhong9, William W. Freimuth9 and Michelle Petri10, 1Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2North Shore-LIJ Health System, Lake Success, NY, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 5University of Alabama at Birmingham, Birmingham, AL, 6Washington Hospital Center, Washington, DC, 7Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, 8Human Genome Sciences, Inc., Rockville, MD, 9Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: To update belimumab safety and efficacy data over 7 y in patients with active SLE.  Methods: 449 SLE patients with SELENA-SLEDAI scores ≥4 were enrolled…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology